CLINICAL TRIALS, STUDIES, REGISTRIES, DATA

The focal point of the study is the growing role of machine learning in wearables. Peer-reviewed research from PubMed, MDPI, ScienceDirect, and other leading sources for scientific and medical research proves that monitoring vital signs, such as heart rate, can support the early detection of health risks and potentially reduce reliance on traditional in-person medical examinations.

“These findings demonstrate that mental health factors like anxiety play a critical role in the clinical course of IBD,” said Beth Houck, CEO, SonarMD “By identifying and addressing psychological contributors, we can refine value-based care models to better support patients with chronic digestive diseases. Integrated care models that incorporate mental health screening and interventions should be considered a standard for high-quality IBD care.”

Hugh Salter, Chief Scientific Officer at Anocca, elaborated, "KRAS is an immensely important target in many cancer types, but has to date been challenging to address. KRAS mutations are a hallmark of PDAC, which is among the most difficult to treat cancers, and we believe TCR-T cell therapies and, in particular, our VIDAR-1 assets can be effective in addressing this target and providing a new solution in an indication with high unmet medical need.”

The paper describes the medicinal chemistry optimisation of a new series of ENaC blockers, resulting in the invention of ETD001, Enterprise’s lead asset, a potential new inhaled treatment for cystic fibrosis notes Enterprise Therapeutics.

“We developed LithiX to improve the IVL treatment of calcified lesions with shorter procedure times and effectiveness across a broad range of calcified lesions, and we’re delighted with the PINNACLE I study outcomes demonstrating its sustained safety and effectiveness,” said Motasim Sirhan, CEO of Elixir Medical. “Our team is committed to developing transformative cardiovascular technologies that deliver improved physician experiences and most importantly, better clinical outcomes for patients.”

"These findings are a key step toward informing the medical community of the long-term effectiveness with radiofrequency renal denervation as a treatment for uncontrolled hypertension," stated Dr. David Kandzari, Chief of Piedmont Heart Institute and Cardiovascular Services and lead principal investigator of the SPYRAL HTN-ON MED trial. "Importantly, at two years, we continue to see Symplicity is safe and consistent with clinically meaningful and significant blood pressure reductions. These data further substantiate sustained blood pressure reductions consistently observed in across the SPYRAL and Global Symplicity clinical programs."

Trial investigators presented the data today during a late-breaking clinical trials session at Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation (CRF) and published simultaneously in The New England Journal of Medicine notes Edward Life Sciences.